2024-09-06 - Analysis Report
##  ABBV Stock Analysis: 

**Company Overview:** AbbVie Inc. (ABBV) is a global pharmaceutical company that develops and markets a diverse portfolio of medicines, primarily in the areas of immunology, oncology, neurology, and eye care. 

**Performance Analysis:**

1. **Relative Performance:** ABBV has outperformed the S&P 500 (VOO) by 16.72% in terms of cumulative returns. The stock has exhibited a strong relative performance, currently exceeding the benchmark's return by a significant margin. Its relative strength has been consistent, maintaining its position within the top 65% of its historical performance range. 

2. **Price Momentum:** ABBV's recent price movements suggest a bullish trend. The stock's closing price is currently above its 5-day, 20-day, and 60-day moving averages, indicating a positive momentum in the short to medium term. 

3. **Technical Indicators:** 
    * **RSI (74.27):** ABBV's RSI suggests the stock is currently in overbought territory. 
    * **PPO (-0.36):** ABBV's PPO indicates a slight bearish momentum, but it's important to note that the signal may not be significant given the stock's current price trend.
    * **Delta_Previous_Relative_Divergence (-3.27):**  The recent 20-day relative divergence suggests a minor short-term downward trend.
    * **Expected Return (16.29%):** ABBV's projected expected return of 16.29% suggests a positive outlook for potential future returns over the next five years.  

4. **Recent Earnings & Outlook:** 
    * ABBV has consistently exceeded analysts' EPS expectations in the past five quarters. 
    * In the most recent quarter (2024-07-25), ABBV reported EPS of 2.65, surpassing the estimated EPS of 2.57. 
    * This consistent earnings performance, combined with the positive outlook indicated by the expected return, points towards a healthy and promising financial picture for ABBV.

**Overall Analysis:**

ABBV's current analysis presents a mixed picture. While the stock exhibits strong relative performance, positive price momentum, and a healthy earnings track record, its RSI suggests a potentially overbought condition.  The expected return provides a positive outlook for future growth, but the slightly bearish PPO and negative short-term divergence may indicate a slight correction in the near future. Investors should monitor these indicators and consider their individual risk tolerance when deciding whether to buy or hold ABBV. 
